Human CD47/B2M Double Knockout Cell Line-K562
Cat.No. : CSC-RT2757
Host Cell: K562 Target Gene: CD47, B2M
Size: 1x10^6 cells/vial, 1mL Validation: Sequencing
Inquire for Price
Cell Line Information
Cell Culture Information
Safety and Packaging
| Cat. No. | CSC-RT2757 |
| Cell Line Information | This cell is a stable cell line with a homozygous double knockout of human CD47 and B2M using CRISPR/Cas9. |
| Target Gene | CD47, B2M |
| Host Cell | K562 |
| Size Form | 1 vial (>10^6 cell/vial) |
| Shipping | Dry ice package |
| Storage | Liquid Nitrogen |
| Species | Human |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Inquiry
Background
CD47 encodes a transmembrane protein that is widely expressed on different cell types. By interacting with signal regulatory protein α (SIRPα) on macrophages, CD47 signals to inhibit phagocytosis, allowing the cell to evade immune surveillance. Cancer cells often exploit this mechanism to avoid destruction by the immune system. Overexpression of CD47 has been observed in many types of cancer, making it a promising therapeutic target. Antibodies that block the CD47-SIRPα interaction are currently being developed and tested in clinical trials, aiming to enhance the immune system's ability to target and eliminate cancer cells.
Beta-2-microglobulin (B2M) is a component of the major histocompatibility complex (MHC) class I molecule, which is present in nearly all nucleated cells. B2M is associated with the heavy chain of MHC class I molecules and is essential for their stability and trafficking to the cell surface. Proper expression of MHC class I molecules is essential for immune recognition by cytotoxic T lymphocytes, which detect and eliminate cells that present abnormal antigens, such as those from viruses or transformed cancer cells. Mutations or alterations in the B2M gene can lead to loss of MHC class I expression, which can result in immune evasion. This phenomenon has been observed in various cancers, where loss of B2M expression is associated with poor prognosis and resistance to immune checkpoint blockade therapy.
For research use only. Not intended for any clinical use.
